Custom Approach to Enhance Clinical Data Mining
News Oct 01, 2014
LabConnect’s BioVisualization is a proprietary and customizable software platform that queries clinical sample database(s) in real time to analyze and provide visual interpretations of a project’s data. This unique platform is designed to quickly generate customizable figures, which can be downloaded and shared among colleagues and incorporated into reporting documents.
“Large, complex datasets generated throughout the course of a clinical trial make finding underlying trends challenging,” said Eric Hayashi, president and CEO. “LabConnect’s BioVisualization tool makes it possible to visualize this data and find greater meaning using fewer resources. This inventive platform creates an opportunity to make critical decisions a lot sooner.”
LabConnect’s white paper, “BioVisualization: Custom Approaches to Enhance Clinical Data Mining,” provides an overview of visual data analysis tools, their benefits and how this technology is being implemented by pharmaceutical companies of all sizes to make critical decisions faster and with lower costs. This informative white paper is now available for download.
“The scale of datasets has become overwhelming, making analysis of this information tedious and resource-draining,” said Hermioni Zouridis, senior scientist of scientific operations at LabConnect. “Unlike pre-programmed platforms, versatile visual data analytics tools enable researchers to generate customizable figures, helping identify trends in study results faster and ultimately making it possible to bring drugs to market sooner.”
The architecture of each person’s brain is unique, and differences may influence how quickly people can complete various cognitive tasks.o learn more, scientists are developing a new tool — computational models of the brain — to simulate how the structure of the brain may impact brain activity and, ultimately, human behavior.READ MORE
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019